These observations highlight the crucial role of FOXM1 in promoting the progression and metastasis of TNBC, and suggest that these compounds may hold promise for therapeutic intervention against TNBC, with the aim of reducing tumor progression and metastatic outgrowth, and hopefully might ultimately provide clinical benefit to patients with this aggressive type of breast cancer. The gene discussed is FOXM1; the disease is breast carcinoma.